---
title: "Arbutus Biopharma Ends RSV Agreement With Genevant; Receives $1 Million Termination Fee"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292898996.md"
description: "Arbutus Biopharma terminated its RSV Agreement with Genevant Sciences on July 15, 2026. The agreement previously addressed damages allocation tied to Moderna’s mRESVIA vaccine. Following a broader settlement with Moderna that did not allocate proceeds to mRESVIA, the parties mutually ended the arrangement. As part of the termination, Genevant will pay Arbutus a $1.0 million fee within ten business days."
datetime: "2026-07-16T11:33:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292898996.md)
  - [en](https://longbridge.com/en/news/292898996.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292898996.md)
---

# Arbutus Biopharma Ends RSV Agreement With Genevant; Receives $1 Million Termination Fee

Arbutus Biopharma terminated its 2025 RSV Agreement with Genevant via a Termination Agreement dated Jul 15, 2026. The arrangement, which addressed allocation of damages or settlement proceeds tied to Moderna’s mRESVIA vaccine, is fully ended, with Genevant to pay Arbutus a $1.0 million termination fee within ten business days. The move follows a broader settlement with Moderna that did not specifically allocate proceeds to mRESVIA.

**Agreement details:**

-   **Agreement terminated**: RSV Agreement on mRESVIA-related damages allocation
-   **Counterparty**: Genevant Sciences
-   **Termination date**: Jul 15 2026
-   **Termination type**: mutual
-   **Exit fees / payments**: $1.0 million
-   **Reason**: Settlement lacked mRESVIA allocation; parties ended allocation arrangement

Original SEC Filing: Arbutus Biopharma Corp \[ ABUS \] - 8-K - Jul. 16, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ABUS.US](https://longbridge.com/en/quote/ABUS.US.md)
- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [MRNX.US](https://longbridge.com/en/quote/MRNX.US.md)
- [MRNY.US](https://longbridge.com/en/quote/MRNY.US.md)

## Related News & Research

- [Moderna (MRNA) Stock Looks Above Fair Value After Cancer Trial News](https://longbridge.com/en/news/293731075.md)
- [Moderna (MRNA) Beat Revenue Views, Is The Stock Now Too Expensive?](https://longbridge.com/en/news/294387965.md)
- [Moderna (MRNA) Adds Finance Veteran To Its Board, Is The Stock Fully Valued?](https://longbridge.com/en/news/293478959.md)
- [Moderna wins EU contract for RSV vaccine supply](https://longbridge.com/en/news/292189866.md)
- [Moderna (MRNA) Stock Looks Stretched On Sales But Reasonable On Momentum](https://longbridge.com/en/news/292799347.md)